Mulya.ai
Ticker
WST
Scenario
Key Inputs
Revenue est.?Analysttaper yr5
OP margin est.?Analyst
Reinvestment est.?projected
R&D capitalizedNo
Leases factoredNo
Key Assumptions
WACC ?9.3%
ERP ?4.5%
Risk-free rate ?4.1%
Beta (blended) ?1.151
Beta (levered) ?1.162
Terminal OM% ?17.7%
Segment conc. ?81% dominant
Terminal growth ?4.1%
Bond rating ?AAA · 0.60%
ROIC option ?Opt 4 · 18.2%
Prob of failure ?0.0%
Pipeline validated · 2026-05-17

WST · West Pharmaceutical Services, Inc.

$254.802026-05-17
Sector: Healthcare; Industry: Medical - Instruments & Supplies; Sub-Industry: Health Care Supplies

Intrinsic Value Range Comparison · Mulya.ai

Bull
$149
-41.4% vs market
Base · active
$129
-49.4% vs market
Bear
$123
-51.7% vs market
Mulya.ai vs Analyst IV Comparison?
Bear $123
Base $129
Bull $149
Market $255
Median $305
Market Price $255
Mulya.ai Base $129
Analysts Median $305
Mulya.ai IV range ($123 · $149)
Analysts Range ($265 · $340)
Fundamentals · historical + forward · base
italics = DCF projection
PeriodRevenueRev Gr ?Ops M% ?Tax Rate ?NOPAT ?
Reinvest ?
FCFF ?WACC% ?PV FCFF ?ROIC ?Inv. Cap ?EPS ?P/E
2021.Q4$2.8B26.8%13.9%$653MM−$327MM$326MM8.3%35.6%$1.8B$9.10
2022.Q4$2.9B1.9%26.5%16.4%$639MM−$175MM$463MM9.2%33.2%$2.0B$8.06
2023.Q4$3.0B2.3%24.1%17.1%$589MM−$245MM$344MM8.8%27.6%$2.3B$8.16
2024.Q4$2.9B-2.0%20.6%17.9%$488MM−$219MM$269MM9.5%20.9%$2.4B$6.78
2025.Q4$3.1B6.3%20.1%19.8%$495MM−$50MM$445MM9.5%19.7%$2.6B$6.7930.0
italics below = DCF projection · 10yr Rev CAGR: 5.5%
2026.Q4$3.2B+5.7%20.1%19.8%$525MM−$79MM$446MM9.2%$409MM19.8%$2.7B$7.2235.3
2027.Q4$3.5B+6.3%20.1%19.8%$558MM−$108MM$450MM9.1%$377MM20.3%$2.8B$7.6733.2
2028.Q4$3.7B+7.1%20.1%19.8%$597MM−$160MM$437MM9.1%$336MM20.8%$3.0B$8.2131.0
2029.Q4$3.9B+6.3%20.1%19.9%$635MM−$193MM$441MM9.0%$312MM20.8%$3.1B$8.7329.2
2030.Q4$4.2B+5.9%20.1%19.9%$672MM−$195MM$477MM9.0%$309MM20.7%$3.3B$9.2427.6
Term. Yr+$5.5B4.1%17.7%20.0%$779MM−$175MM$603MM8.6%$5.7B18.2%
Active scenario IV: $129 (-49.4% vs market)